<h3 style="text-align:center;"><a href="${link:{uuid:{3c621072-b317-4715-bb3e-c63ceb933735},repository:{dam},path:{/Portal/UK/Prescribing-links/Dupixent-AD-and-PN-GB-PI.pdf}}}">Dupixent (dupilumab) Prescribing Information UK</a></h3>

<h3>When to use advanced therapy? – Dr Tom King</h3>
Watch Dr Tom King discuss when to transition to advanced therapy and how to select an appropriate treatment choice for patients with moderate-to-severe AD.&nbsp;
Video Playtime: 7mins 13secs

<h3>What have we learnt from 8 years of experience with DUPIEXNT? – Nicola Housam&nbsp;&nbsp;</h3>
Watch Nicola Housam discuss why real-world evidence is important and how this, combined with her experience of DUPIXENT, has impacted how she runs her biologic clinics.
Video Playtime: 4mins 58secs

<h3>Dupixent in patients as young as 6 months old with severe AD – expert panel discussions</h3>
Watch a panel of experts discuss the practicalities of using DUPIXENT in children aged &lt;12 years through real-world case studies.
&nbsp;Video Playtime: 48mins 05secs

<h3>DUPIXENT use in a 3-year old patient – Dr. Gabriela Petrof</h3>
Watch Dr. Gabriela Petrof present a case study of the use of DUPIXENT in a 3-year old patient with severe atopic dermatitis.
Video Playtime: 7mins 07secs

<h3>DUPIXENT use in a child patient with severe AD – Dr. Inge Kreuzer-Genis &amp; Emily King</h3>
Watch Dr. Inge Kreuzer-Genis and Emily King present a clinical case study of the use of DUPIXENT in an 8-year old patient with severe atopic dermatitis.
Video Playtime: 13mins 52secs

<h3>Conjunctivitis Management - Mr Scott Robbie</h3>
Watch Mr Scott Robbie discuss management of conjunctivitis in AD patients.
Video Playtime: 1min 45secs

<h2>Patient Guides</h2>
Please click below for available patient guides for patients prescribed with Dupixent:&nbsp;

DUPIXENT (dupilumab) Prescribing Information UK

SPECIALTY-CARE

DUPIXENT

ATOPIC-DERMATITIS

DERMATOLOGY

Dupixent (dupilumab) Resources

<a href="${link:{uuid:{3c621072-b317-4715-bb3e-c63ceb933735},repository:{dam},path:{/Portal/UK/Prescribing-links/Dupixent-AD-and-PN-GB-PI.pdf}}}">Dupixent (dupilumab) Prescribing Information UK</a>

DE:RM is Sanofi’s flagship annual promotional meeting, bringing together healthcare professionals from across the UK who are dedicated to the care of people living with atopic dermatitis (AD). Curated in collaboration with expert Chairs in AD management, DE:RM offers a balanced, one-day agenda featuring diverse speakers and discussion topics. The meeting explores the evolving treatment landscape, including the appropriate use of Dupixent (dupilumab) and other biologic therapies. DE:RM is designed to foster clinical excellence, collaboration, and innovation in dermatology.
 
 &nbsp;
<h2>Disease Modification – Q&amp;A with Prof Stephan Weidinger</h2>

Listen to Prof Stephan Weidinger, a leading dermatologist, express his opinions on how the concept of disease modification is impacting care for atopic dermatitis patients and its future potential applications.

<h2>Disease Modification: It's More Than Just Atopic Dermatitis - Prof Stephan Weidinger</h2>

Learn from Prof Stephan Weidinger as he discusses Type 2 Inflammation and the multifactorial burden of AD and explore the possible components of on-therapy disease modification for AD patients.

<h2>Managing Tolerability Issues When on Advanced Therapies – Panel Presents</h2>

Join our Dermatology panel as they discuss adverse events associated with advanced therapies in patients with AD and explore potential management strategies through real-life case studies.

<h2>What To Choose and How To Use in Your Paediatric Patients – Prof Tess McPherson</h2>

Hear from Prof Tess McPherson as she discusses the characteristics and burden of childhood AD, discuss the treatment options available, with useful tools on how to support patients and families through the treatment pathway.

<h2>Understanding Atopic Dermatitis in Skin of Colour – Teena Mackenzie</h2>

In this insightful video, Nurse Consultant Teena Mackenzie explores the unique challenges and considerations in diagnosing and treating atopic dermatitis (AD) in patients with skin of colour. Drawing from clinical experience and educational initiatives, she highlights the importance of accurate assessment, cultural sensitivity, and holistic care. The session also covers EASI scoring nuances, pigmentation differences, and the impact of underrepresentation in dermatology education and research.

<h2>Type 2 Inflammation Panel Discussion</h2>

This engaging panel discussion brings together leading dermatology and respiratory experts to explore the complexities of type 2 inflammation across multiple comorbidities, including atopic dermatitis, asthma, and eosinophilic esophagitis. Through a real-world case study of a 17-year-old patient, the panel highlights the importance of integrated care, biomarker-driven treatment decisions, and the role of DUPIXENT in managing type 2 inflammatory conditions. A must-watch for anyone looking to deepen their understanding of holistic patient management and the evolving treatment landscape.

<h2 style="text-align: center;">Discover other resources
 
 &nbsp;</h2>

Link to Prescribing Information can be found below.

DE:RM – Dermatology Excellence: Redefining Management

This section has resources that you may require for your formulary submissions and business cases or policy reviews. As well as product information, therapy support resources and treatment guidelines. You can download these materials to better support your decision making.

This document provides factual and technical information about Dupixent to support relevant local formulary applications for CRSwNP.

Dupixent® (dupilumab) Formulary Application Support Pack for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Download this resource for suggested guidance on the development of a standard operating procedure (SOP) for delivery of teplizumab infusions.

Tzield®▼ (teplizumab) SOP Template

Download this leave piece to understand the therapeutic value and potential cost benefits of TZIELD for payers and commissioners.

Tzield®▼ (teplizumab) Value Proposition Leave Piece

Information and guidance to support healthcare professionals and other relevant decision-makers to build a local business case for a TZIELD infusion delivery service.

Tzield
 
 Business Case Template

Watch this practical video where Alison Tennant talks through funding and service models for a Tzield infusion service, including common barriers and possible solutions.

Hear from ex-Commissioner on funding &amp; service models for Tzield

This document supports clinical teams and service commissioners in understanding the operational requirements, patient pathways, staffing needs and logistical considerations necessary to delivery the 14-day infusion treatment safely &amp; effectively. Based on the:
<ul>
 <li>Product SmPC</li>
 <li>Expert advisory board feedback</li>
 <li>Real-world experience of TZIELD® delivery through a Managed Access Programme.</li>
</ul>

Tzield &nbsp;Service Consideration Guide &amp; Checklist

This document provides factual and technical information about TZIELD to support your understanding of the product and relevant documentation for local formulary applications.

Tzield®▼ (teplizumab) Information Guide

Case study from Birmingham, with practical, peer-to-peer insights and transferable learnings from a real-world implementation, covering how clinical, pharmacy, and nursing teams overcame operational challenges to deliver a 14-day infusion service within existing NHS infrastructure. Insights from the following healthcare professionals:
<ul>
 <li>Adults – Professor Parth Narendran</li>
 <li>Paediatrics – Renuka Dias</li>
 <li>Principal Pharmacist – Tayebah Abbasi
 
 
 &nbsp;</li>
</ul>

Tzield Birmingham Case Study&nbsp;
 
 &nbsp;

We have a range of cost models available. If you need a more detailed modelling of our basal and rapid acting insulins portfolio, please reach out to one of our representatives.

Looking for something else?

black

This document provides information on estimating patients who might be eligable for Dupixent® (dupilumab) via the COPD indication.

COPD - Eligible Population Estimator

Explore the impact that biologics could have on COPD services in regard to costs, admissions and stays within hospital.

COPD - Burden Analysis Model

An infographic showing the burden of COPD on hospital admissions, bed days and length of stay in England. For data relating to your ICB, please Get in Touch via the link below.

Burden of COPD Infographic

Get in Touch with the Health System Solutions Team

Resources to inform, aid and give insight across therapy areas, to help implement strategies to reduce inequalities in healthcare.

Formulary & Service Support

OUT-OF-TAXONOMY

PAYOR

Prescribing information is available by clicking the link at the bottom of the page

<h3>Toujeo®&nbsp;SoloStar®&nbsp;Handbook</h3>
This comprehensive handbook can help your patients use their Toujeo®&nbsp;SoloStar® pen. It has information on Toujeo®&nbsp;and how to inject and adjust their insulin using the SoloStar®&nbsp;pen. The handbook can help you support your patients in making a positive start to managing their diabetes with Toujeo®&nbsp;SoloStar®.

<h3>SoloStar®&nbsp;Patient Instruction Video</h3>
Patients who have newly started on insulin therapy or a new device may need that extra reassurance. This video can help support patients who have recently started on Toujeo®&nbsp;SoloStar®, in making a positive start with their new device. It helps them to get familiar with the pen and gives step by step instructions on how to inject insulin.

GENERAL-MEDICINES

TOUJEO

INTEGRATED-DIABETES-CARE

DIABETES

Toujeo SoloStar (insulin glargine 300 units/mL) patient materials

<h3>Monitoring your daily blood glucose</h3>
Your patients can fill in this diary to help monitor their daily blood glucose level. Doing this can support them in making the right adjustments to their insulin doses. It also helps keep a record of any appointments with their diabetes nurse or doctor.

Toujeo®

Support materials for patients prescribed Trurapi. For more materials and patient support, see our dedicated patient website <a href="https://www.mysanofiinsulin.co.uk/trurapi/" target="_blank">My Sanofi Insulins</a>
Prescribing information is available at the bottom of this page in the Product Card.

<h3>Trurapi Patient Handbook</h3>
This comprehensive handbook will support your patients that have been prescribed Trurapi. It contains information about Trurapi, how it works and how to use it. This handbook will help you support your patients in making a positive start to managing their diabetes with Trurapi.

<h3>Trurapi Solostar Handbook</h3>
This handbook can give your patients confidence to use their Trurapi Solostar pen. They can read how to store, prepare and inject insulin with the SoloStar pen.

<h3>Blood glucose monitoring diary</h3>
Your patients can fill in this diary to help monitor their daily blood glucose level. Doing this can support them in making the right adjustments to their insulin doses. It also keeps a record of any appointments with their diabetes nurse or doctor.

Trurapi®

TYPE-2-DIABETES

Trurapi (insulin aspart 100u/mL) Patient Materials

<h3>Toujeo®&nbsp;DoubleStarTM&nbsp;Handbook</h3>
This comprehensive handbook can help to give your patients confidence in using their device. It has information on Toujeo and how to inject and adjust their insulin using the DoubleStar pen. The handbook can help you support your patients in making a positive start to managing their diabetes with Toujeo DoubleStar.

<h3>DoubleStarTM Patient Instruction Video</h3>
Patients who have newly started on insulin therapy or a new device may need that extra reassurance. This video has been developed to help support patients who have recently started on Toujeo®&nbsp;DoubleStarTM&nbsp;in making a positive start with their new device. It helps them to get familiar with the pen and gives step by step instructions on how to inject insulin.

Toujeo DoubleStar (insulin glargine 300 units/mL) patient materials

<h3>Your Guide to Lantus®</h3>
This comprehensive handbook will support your patients that have been prescribed Lantus. It contains information about Lantus, how it works and how to use it. This handbook will help you support your patients in making a positive start to managing their diabetes with Lantus.

<h3>Lantus® SoloStar Handbook</h3>
This handbook can give your patients confidence to use their Lantus Solostar pen. They can read how to store, prepare and inject insulin with the SoloStar pen.

<h3>Home Monitoring Diary</h3>
Your patients can fill in this diary to help monitor their daily blood glucose level. Doing this can support them in making the right adjustments to their insulin doses. It also keeps a record of any appointments with their diabetes nurse or doctor.

Lantus (insulin glargine 100u/mL) Patient Materials

To order hardcopy patient materials, Sanofi have invested in a self-serve Medisa portal. To access the portal and order materials, click on <a href="https://www.medisa.com/medisa/">this link</a>.
Our patient materials and more support resources are available on our dedicated patient website <a href="https://www.mysanofiinsulin.co.uk/">My Sanofi Insulins</a>.

<h3>Toujeo® DoubleStar™
 
 (insulin glargine 300 units/mL)</h3>
<a href="${link:{uuid:{f34a87f8-75d0-4459-a2d8-c10d6469758f},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo-combined.pdf}}}">Prescribing information UK</a>

<h3>Toujeo® SoloStar™
 
 (insulin glargine 300 units/mL)</h3>
<a href="${link:{uuid:{f34a87f8-75d0-4459-a2d8-c10d6469758f},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo-combined.pdf}}}">Prescribing information UK</a>

<h3>Lantus® SoloStar™
 
 (insulin glargine 100 units/mL)</h3>
<a href="${link:{uuid:{97e86e26-07fe-49e8-b6f3-31758c4a1495},repository:{dam},path:{/Portal/UK/Prescribing-Information/Lantus_GB.pdf}}}">Prescribing information UK</a>

<h3>Trurapi®
 
 (insulin aspart 100 units/mL)</h3>
<a href="${link:{uuid:{62efcdcd-db16-49b4-8041-55c212a401fa},repository:{dam},path:{/Portal/UK/Prescribing-Information/Trurapi-PI-GB-April-2023.pdf}}}">Prescribing information UK</a>

Patient materials

Ask us your questions about our products, patient materials or organising a meeting.

Sanofi is here to support you and your patients

Diabetes patient support

DIABETES-NON-CORE

DIABETES-CORE

LANTUS

<a href="${link:{uuid:{55f30477-c7e2-49c0-8cfc-16966f28d4c2},repository:{dam},path:{/Portal/UK/Prescribing-links/Praluent-PI-UK.pdf}}}" target="_blank">Prescribing Information (UK)</a>

Disclaimer: The resources contained within this section are updated regularly by Sanofi. Before you use any of the resources, or provide any resources to your patients please re-visit this page to ensure that you are using the most up-to-date version(s).

<h3>Praluent®</h3>
Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.

<a>More about Praluent®</a>

<h3>Patient Website</h3>
Find resources and support for your patients on Praluent®. Find useful links about how patients can manage their cholesterol.

FOUNDATION-NON-CORE

CV-T-CORE

ROSUVASTATIN-SANOFI

PRALUENT

ZENON

DYSLIPIDEMIA

CARDIOLOGY

Download a letter to give to patients starting on Praluent

<h3>Resources for Praluent®&nbsp;</h3>

▶ Praluent&reg;&nbsp;Injection Guide (PDF)

▶ Living with High Cholesterol (PDF)

Praluent® (alirocumab) - Comprehensive Support for the Praluent® Patient

▶ How to Inject Praluent®&nbsp;(video)

Website: MyPraluent&reg;&nbsp;- This website was developed and funded by Sanofi

Patient Information Leaflet 75mg (sourced from Medicines.org.uk)

Patient Information Leaflet 150mg (sourced from Medicines.org.uk)

Patient Information leaflet 300mg (sourced from&nbsp;Medicines.org.uk)

Homecare is run by experienced pharmacists who dispense Praluent®&nbsp;and arrange delivery to patients.

<a href="/uk/dyslipidaemia">SEE MORE FROM SCIENCE</a>

Get in touch with the Dyslipidaemia Team

Praluent® (alirocumab) Prescribing Information (UK)

To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

Quick Summary

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

Share via {platform} (opens email client)

Cause And Symptoms

Complications

Diagnosis And Treatment

Overview

Prevention

References

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

There are no upcoming events

Showing {start}–{end} of {total} events

Event details

Check back later for upcoming events, or browse all available events across therapeutic areas.

There are no events scheduled for this therapeutic area

Something went wrong

Try a different keyword, date range, or venue.

No matching events

Registration information

Success! We've received your request

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are about to leave Sanofi campus website.

You are about to leave Campus.sanofi/uk.

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

Title should not exceed 100 characters

Enter your title

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v7.0) - Date of Preparation: July 2025

Welcome to Sanofi Campus UK

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Review the materials in your cart before checkout.

Browse and order materials for your practice.

Filters

Materials

Cart

Checkout

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Resources